Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECONNECT
2024-513888-99-00Phase 3Completed
- Sponsor
- Harmony Biosciences
- Start
- Nov 2024
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Fragile X syndrome (FXS) comparing ZYN002 transdermal gel cannabidiol with Placebo transdermal gel (2 arms). Started Nov 2024; status: completed.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2024-513888-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513888-99-00.